Sloan Sheldon has filed 15 insider transactions across 1 company since October 2024.
Most recent transaction: a option exercise of 78333 shares of Spyre Therapeutics, Inc. ($SYRE) on May 01, 2026.
Activity breakdown: 0 open-market purchases and 8 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | M | Stock Option (Right to Buy) | 78333 | $0.00 | 321,667.0000 | 78,540,164 | 19.58% | 0.10% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 19656 | $70.61 | 37,371.0000 | 78,540,164 | 34.47% | 0.03% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 8777 | $71.56 | 28,594.0000 | 78,540,164 | 23.49% | 0.01% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 12777 | $72.94 | 15,817.0000 | 78,540,164 | 44.68% | 0.02% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 10358 | $73.74 | 5,459.0000 | 78,540,164 | 65.49% | 0.01% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 5059 | $74.60 | 400.0000 | 78,540,164 | 92.67% | 0.01% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 400 | $75.37 | 0.0000 | 78,540,164 | 100.00% | 0.00% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | M | Common Stock | 78333 | $27.46 | 78,333.0000 | 78,540,164 | 9999.99% | 0.10% |
| May 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 21306 | $69.53 | 57,027.0000 | 78,540,164 | 27.20% | 0.03% |
| April 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | M | Common Stock | 7958 | $21.66 | 7,958.0000 | 78,540,164 | 9999.99% | 0.01% |
| April 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | S | Common Stock | 7958 | $50.00 | 0.0000 | 78,540,164 | 100.00% | 0.01% |
| April 1, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | M | Stock Option (Right to Buy) | 7958 | $0.00 | 87,542.0000 | 78,540,164 | 8.33% | 0.01% |
| Jan. 9, 2026 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 77,592,130 | 9999.99% | 0.18% |
| Jan. 15, 2025 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | A | Stock Option (Right to Buy) | 95500 | $0.00 | 95,500.0000 | 0 | 9999.99% | 0.00% |
| Oct. 1, 2024 | Spyre Therapeutics, Inc. | $SYRE | Sloan Sheldon | Chief Medical Officer | A | Stock Option (Right to Buy) | 400000 | $0.00 | 400,000.0000 | 0 | 9999.99% | 0.00% |